| Literature DB >> 21392444 |
Brigitte A G L van Cleef1, Dominique L Monnet, Andreas Voss, Karina Krziwanek, Franz Allerberger, Marc Struelens, Helena Zemlickova, Robert L Skov, Jaana Vuopio-Varkila, Christiane Cuny, Alexander W Friedrich, Iris Spiliopoulou, Judit Pászti, Hjordis Hardardottir, Angela Rossney, Angelo Pan, Annalisa Pantosti, Michael Borg, Hajo Grundmann, Manica Mueller-Premru, Barbro Olsson-Liljequist, Andreas Widmer, Stephan Harbarth, Alexander Schweiger, Serhat Unal, Jan A J W Kluytmans.
Abstract
To estimate the proportion of methicillin-resistant Staphylococcus aureus (MRSA) isolates from humans that were sequence type (ST) 398, we surveyed 24 laboratories in 17 countries in Europe in 2007. Livestock-associated MRSA ST398 accounted for only a small proportion of MRSA isolates from humans; most were from the Netherlands, Belgium, Denmark, and Austria.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21392444 PMCID: PMC3166010 DOI: 10.3201/eid1703.101036
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Characteristics of laboratories that reported MRSA and livestock-associated MRSA ST398 isolates from human samples, Europe, 2007*
| Laboratory no. | Country | Type of laboratory | Source of MRSA isolates | No. MRSA isolates received | No. MRSA isolates typed | MRSA ST398 isolates | |
|---|---|---|---|---|---|---|---|
| No. (%) | 95% CI | ||||||
| 1 | Austria | National ref | All | 523 | 523 | 0 | 0–0.7 |
| 2 | Austria | National ref | All | 586 | 586 | 16 (2.7) | 1.7–4.4 |
| 3 | Belgium | National ref | All | 329 | 149 | 7 (4.7) | 2.3–9.4 |
| 4 | Czech Republic | National ref | Blood | 37 | 10 | 0 | 0–27.8 |
| 5 | Denmark | National ref | All | 659 | 659 | 14 (2.1) | 1.3–3.5 |
| Denmark | National ref | Clinical | 370 | 370 | 6 (1.6) | 0.7–3.5 | |
| 6 | Finland | National ref | All | 1,323 | 1,323 | 1 (0.1) | 0–0.4 |
| 7 | Germany | National ref | Clinical | 1,293 | 1,293 | 9 (0.7) | 0.4–1.3 |
| 8 | Germany | Regional ref | Clinical | 866 | 866 | 37 (4.3) | 3.1–5.8 |
| 9 | Greece | National ref | Clinical | 336 | 336 | 0 | 0–1.1 |
| 10 | Hungary | National ref | All | 365 | 63 | 0† | NA |
| 11 | Iceland | National ref | Clinical | 21 | 21 | 0 | 0–15.5 |
| 12 | Italy | National ref | Clinical | 108 | 108 | 1 (0.9) | 0.2–5.1 |
| 13 | Ireland | National ref | Clinical | 832 | 696 | 0 | 0–0.5 |
| 14 | The Netherlands | National ref | Clinical | 478 | 478 | 57 (11.9) | 9.3–15.1 |
| 15 | The Netherlands | Local | Clinical | 12 | 12 | 3 (25.0) | 8.9–53.2 |
| 16 | Sweden | National ref | All | 1,127 | 1,127 | 8 (0.7) | 0.4–1.4 |
| 17 | Switzerland | Local | Clinical | 587 | 65 | 0† | NA |
| 18 | Switzerland | Regional ref | All | 182 | 182 | 0 | 0–2.1 |
| 19 | Switzerland | Regional ref | Clinical | 64 | 64 | 0 | 0–5.7 |
| 20 | Switzerland | Local | All | 80 | 78 | 0 | 0–4.7 |
| 21 | Turkey | Local | Clinical | 198 | 60 | 0 | 0–6.0 |
*MRSA, methicillin-resistant Staphylococcus aureus; ST398, sequence type 398; CI, confidence interval; ref, reference laboratory; NA, not applicable. †Not reported because laboratory typed <25% of MRSA isolates.
Distribution of typed MRSA ST398 and other MRSA clinical isolates, by body site, 7 European countries, 2007*
| Sample source | No. (%) typed clinical isolates | p value† | |
|---|---|---|---|
| MRSA ST398, n = 113 | Other MRSA, n = 3,435 | ||
| Blood | 2 (1.8) | 343 (10.0) |
|
| Respiratory tract | 20 (17.7) | 451 (13.1) | 0.16 |
| Skin and wound | 76 (67.3) | 2,312 (67.3) | 0.99 |
| Urinary tract | 6 (5.3) | 173 (5.0) | 0.90 |
| Other | 9 (8.0) | 156 (4.5) | 0.09 |
*Only data from 9 national or regional laboratories in the 7 countries that reported clinical isolates and typed all these isolates were included. Boldface indicates statistical significance (p<0.05). MRSA, methicillin-resistant Staphylococcus aureus; ST398, sequence type 398. †χ2 test.